Compounds for treatment of cancer

1. A compound of the structure of formula XXV:

wherein

R 4 , R 5 and R 6 are independently hydrogen, O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CF 3 , CN, —CH 2 CN, NH 2 , hydroxyl, —(CH 2 ) i NHCH 3 , —(CH 2 ) i NH 2 , —(CH 2 ) i N(CH 3 ) 2 , —OC(O)CF 3 , C 1 -C 5 linear or branched alkyl, haloalkyl, alkylamino, aminoalkyl, —OCH 2 Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH 2 or NO 2 ;

R 9 and R 12 are independently hydrogen, linear or branched, substituted or unsubstituted C 1 -C 5 alkyl, or substituted or unsubstituted C 5 -C 6 cycloalkyl, substituted or unsubstituted aryl, —CH 2 Ph, substituted benzyl, haloalkyl, aminoalkyl, —OCH 2 Ph, substituted or unsubstituted SO 2 -aryl, substituted or unsubstituted —(C═O)-aryl or OH;

wherein the substitutions are independently selected from the group consisting of hydroxyl, aliphatic straight- or branched-chain C 1 to C 10 hydrocarbon, alkoxy, haloalkoxy, aryloxy, nitro, cyano, alkyl-CN, halo, haloalkyl, dihaloalkyl, trihaloalkyl, COOH, C(O)Ph, C(O)-alkyl, C(O)O-alkyl, C(O)H, C(O)NH 2 , —OC(O)CF 3 , —OCH 2 Ph, amino, aminoalkyl, alkylamino, mesylamino, dialkylamino, arylamino, amido, NHC(O)-alkyl, urea, alkyl-urea, alkylamido, haloalkylamido, arylamido, aryl, C 5 to C 7 cycloalkyl, arylalkyl, and combinations thereof;

i is an integer between 0-5; and

n is an integer between 1-3;

or its pharmaceutically acceptable salt, hydrate, polymorph, tautomer or stereoisomer.

2. The compound of claim 1 , wherein said compound is

(4-phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70a);

(4-(4-fluorophenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70b);

(4-(4-chlorophenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70c);

(4-(4-bromophenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70d);

(4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70e);

(4-p-tolyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70f);

(4-(4-methoxyphenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70g);

(4-(4-(dimethylamino)phenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70h);

(4-(4-hydroxyphenyl)-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70i);

(5-methyl-4-phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70j);

(5-ethyl-4-phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70k);

(4-phenyl-5-propyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70l);

(1-methyl-4-phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70m);

(1-ethyl-4-phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70n);

(1-benzyl-4-phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70o); or

(1-cyclopentyl-4-phenyl-1H-imidazol-2-yl)(3,4,5-trimethoxyphenyl)methanone (70p).

3. A method of treating, suppressing, reducing the severity of, reducing the risk of, or inhibiting cancer comprising administering a compound according to claim 1 to a subject having cancer under conditions effective to treat the cancer.

4. A method of treating a drug resistant tumor or tumors comprising administering a compound according to claim 1 to a subject suffering from cancer under conditions effective to treat the drug resistant tumor or tumors.

5. The method of claim 3 , wherein said cancer is selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, skin cancer, melanoma, lung cancer, colon cancer, leukemia, renal cancer, CNS cancer, and combinations thereof.

6. The method of claim 5 , wherein said cancer is metastatic cancer.

7. The method of claim 5 , wherein said administering is carried out in combination with another cancer therapy.

8. The method of claim 4 , wherein said tumor is melanoma cancer tumor.

9. The method of claim 4 , wherein said tumor is metastatic melanoma tumor.

10. The method of claim 4 , wherein said tumor is prostate cancer tumor.

11. The method of claim 4 , wherein said tumor is ovarian cancer tumor.

12. The method according to 4 , wherein said administering is carried out in combination with another cancer therapy.

13. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

14. A method of destroying a cancerous cell comprising providing a compound according to claim 1 and contacting the cancerous cell with the compound under conditions effective to kill the cancer cell.

15. A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier.

16. A method of treating, suppressing, reducing the severity of, reducing the risk of, or inhibiting cancer comprising administering a compound according to claim 2 to a subject having cancer under conditions effective to treat the cancer.

17. A method of treating a drug resistant tumor or tumors comprising administering a compound according to claim 2 to a subject suffering from cancer under conditions effective to treat the drug resistant tumor or tumors.

18. A method of destroying a cancerous cell comprising providing a compound according to claim 2 and contacting the cancerous cell with the compound under conditions effective to kill the cancer cell.